Splicing Alteration TRIZ Cases

Antisense oligonucleotides target mutant H3F3A mRNA to reduce tumor growth and promote neural stem cell differentiation.

Antisense oligomers hybridize to pre-mRNA regions to drive exon 2 inclusion and restore functional acid alpha-glucosidase protein levels.

Inosine-containing oligonucleotides induce dystrophin synthesis while reducing immunogenicity and aggregation.

Antisense oligomers bind COL7A1 pre-mRNA splice junctions to exclude exon 80 and restore functional type VII collagen expression.

Allele-specific splice switching oligonucleotides promote pseudoexon incorporation into mature mRNA transcripts.

Modified oligonucleotides block exon 17 splicing in the APP transcript, preventing gamma-secretase cleavage and reducing neurotoxic Aβ42 levels.

Modified antisense oligonucleotides in AAV vectors restore reading frames, reducing injection frequency and toxicity.

Antisense oligonucleotides bind conserved TDP-43 binding sites on pre-mRNA transcripts, correcting aberrant splicing and restoring normal gene expression.

Antisense oligonucleotides hybridize with CFTR RNA transcripts to modulate splicing, restoring functional protein levels despite persistent lung infections.

Chimeric oligomeric compounds modulate splicing via segmented sugar modifications, resolving RNase H resistance and cellular uptake trade-offs.

Antisense compounds target SMN-NAT to modulate SMN2 splicing, resolving instability of transcripts lacking exon 7 in spinal muscular atrophy.

Small molecules synergize with antisense oligonucleotides to boost dystrophin expression while reducing toxicity and dosing requirements.

Antisense oligonucleotides inhibit mismatch repair proteins to slow DNA repeat expansion rates in neurodegenerative diseases.

Antisense oligonucleotides hybridize to SMN2 pre-mRNA to induce exon 7 inclusion, restoring functional SMN protein levels lost in spinal muscular atrophy.

Splice modulating oligonucleotides engineer neoantigens in cancer cells, bypassing costly patient-specific epitope profiling.

U7snRNA vectors bypass AAV packaging limits by inducing exon 2 skipping to restore functional dystrophin.

Antisense oligonucleotides hybridize to CFTR transcripts to modulate splicing, addressing genetic mutations that cause cystic fibrosis.

A base editor system modifies the KLKB1 polynucleotide to reduce expression and activity of the encoded polypeptide.

Polynucleic acid polymers hybridize to pre-mRNA to remove retained introns, resolving defective protein expression caused by impaired splicing.

Antisense molecules bind specific RNA motifs to induce targeted exon skipping in the dystrophin gene transcript.

DNAJB6-targeting antisense oligonucleotides modulate splicing to reduce pathogenic isoform expression.

An RNA trans-splicing molecule delivers a suicide protein coding sequence to target cells via specific binding.

Synthetic splice-inhibiting oligonucleotides block mirtron splicing during lentiviral packaging to boost vector yields.

An ED-RgE fusion protein directs sgRNA to genomic DNA splicing sites to induce precise deletions.

A peptide nucleic acid derivative targets the SCN9A pre-mRNA splice site to induce exon 4 skipping and reduce Nav1.7 protein expression.

Peptide nucleic acid derivatives bind to the 3' splice site of human SNAP25 pre-mRNA to induce exon skipping and inhibit protein synthesis.

Splice switching oligonucleotides induce exon skipping to knock down NF-kB components, avoiding DNA mutagenesis and cell mortality associated with RNAi.

Antisense oligonucleotides correct splicing defects in GAA pre-mRNA, restoring enzyme activity for patients with the c.-32 IVS1-13 T>G mutation.

Peptide-morpholino conjugates deliver splice switching oligonucleotides to correct CCDC39 mutations, bypassing endosomal entrapment in lung tissue.

Novel antisense oligomers conjugated with cell-penetrating peptides induce exon skipping in the dystrophin gene.

Anti-sense oligonucleotides modulate NOTCH3 mRNA expression by excluding specific exons to alter protein coding regions.

Modified oligomeric compounds degrade aberrant mRNA transcripts via nonsense mediated decay, correcting splicing errors in genetic diseases.

Antisense compounds modulate SMN2 pre-mRNA splicing to increase exon 7 inclusion.

SaCas9 and SluCas9 guide RNAs excise small DMD gene portions, restoring reading frames while minimizing genetic material loss.

Chemical chaperones correct MBTPS1 gene defects to reduce bone matrix degradation and chondrocyte apoptosis in skeletal dysplasia.

Editing genomic sequences restores PTS protein activity in monocytes, resolving weakened immune responses caused by cell-type specific alternative splicing.

Antisense oligonucleotides induce exon skipping in pre-mRNA to remove proteolytic cleavage sites, resolving non-specific inhibition issues.

Nucleic acids target mutated RAS pre-mRNA to exclude exon 3, overcoming resistance from silent mutations.

SSOs induce UMOD exon-skipping to boost AS-UMOD, enhancing mitochondrial metabolism and protecting TAL cells from acute kidney injury.

Antisense oligonucleotides correct aberrant splicing caused by IVS6+4A>T mutations to restore serotonin production.

Combining antisense oligonucleotides with CFTR modifiers restores near-normal protein function by correcting splicing defects.

Morpholino antisense compounds with phosphorus linkages hybridize dystrophin pre-mRNA to induce exon skipping.

Engineered RNA aptamers detect folinic acid, creating modular gene regulatory systems that overcome organism-specific limitations of natural riboswitches.

Antisense oligomers bind pre-mRNA to restore functional acid alpha-glucosidase protein for glycogen storage disease type II treatment.

Splice modulation removes upstream open reading frames from RNA transcripts, enabling targeted gene upregulation where conventional silencing methods fail.

A Panto recombinase protein catalyzes site-specific DNA recombination at unique pox recognition sites.

Antisense oligonucleotides bind mRNA CAG repeats to recruit ADAR enzymes, converting toxic polyglutamine tracts into arginine sequences.

Antisense compounds correct aberrant splicing in the IKBKAP gene, restoring functional IKAP protein production for Familial Dysautonomia treatment.